Actively Recruiting
China Metastatic Liver Cancer Clinical Registry Cohort Database
Led by Anhui Provincial Hospital · Updated on 2026-05-22
2000
Participants Needed
3
Research Sites
261 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are creating a large, standardized clinical registry for patients with metastatic liver cancer. This study, led by the Department of Hepatobiliary Surgery at the University of Science and Technology of China and supported by multiple centers nationwide, aims to collect detailed information on patient characteristics, primary tumors, systemic therapies, and local treatments. The goal is to better understand disease patterns and prognostic factors for secondary liver cancers and to support real-world clinical research. This is an observational registry study where patients receive standard care for metastatic liver cancer based on current guidelines and physician decisions. Treatments may include surgery hepatectomy, ablation, transarterial chemoembolization TACE, systemic chemotherapy, targeted therapy, or immunotherapy. No specific experimental intervention is assigned by investigators, as the registry evaluates standard clinical management in routine practice. Participants will provide baseline clinical data and be followed over time, with outcomes including overall survival up to 10 years, progression-free survival, and treatment-related adverse events within 90 days after treatment. This long-term data collection will help researchers assess real-world outcomes and safety. Participation involves standard clinical care and data collection, with no additional procedures required beyond usual treatment.
CONDITIONS
Brief Title
China Metastatic Liver Cancer Clinical Registry Cohort Database
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with histologically or radiologically confirmed metastatic liver cancer.
- Age 18 years or older.
- Patients who have voluntarily signed the informed consent form.
- Patients with complete baseline clinical data.
You will not qualify if you...
- Patients with primary liver cancer (e.g., hepatocellular carcinoma).
- Patients with other malignant tumors that may interfere with the evaluation of liver metastasis.
- Patients who have previously participated in other interventional clinical trials.
- Patients with severe cognitive disorders or communication barriers that prevent informed consent.
- Patients with incomplete or missing key clinical data.
Research Team
J
Jizhou Wang, MD PhD
L
Lianxin Liu, MD PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here